EP Patent

EP3658189A1 — Formulations of a compound modulating kinases

Assigned to Daiichi Sankyo Co Ltd · Expires 2020-06-03 · 6y expired

What this patent protects

The invention relates to compositions comprising compound I having the following structure: compound I or a pharmaceutically acceptable salt thereof, and a solubilizing agent; a method of manufacturing these compositions; and methods of using them.

USPTO Abstract

The invention relates to compositions comprising compound I having the following structure: compound I or a pharmaceutically acceptable salt thereof, and a solubilizing agent; a method of manufacturing these compositions; and methods of using them.

Drugs covered by this patent

Patent Metadata

Patent number
EP3658189A1
Jurisdiction
EP
Classification
—
Expires
2020-06-03
Drug substance claim
No
Drug product claim
No
Assignee
Daiichi Sankyo Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.